BCL2 and leukemia: However, the use of targeted cell therapies that include a higher number of leukemia-specific T cells compared with unmanipulated DLIs, combined with azacytidine and/or the BCL-2 inhibitor venetoclax, or FLT3 inhibitors such as gilteritinib or sorafenib [45], may provide an added advantage and be able to increase the response rate in patients with hematologic relapse after HSCT.